<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0342895" disease_type="Disease or Syndrome" abbrv="FED">Fish-eye disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FED</z:e>) in humans is characterized by <z:hpo ids='HP_0007759'>corneal opacities</z:hpo> and markedly decreased plasma concentrations of <z:chebi fb="6" ids="39025">high-density lipoprotein</z:chebi> (<z:chebi fb="17" ids="39025">HDL</z:chebi>) cholesterol, <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> (apo) AI, and apo <z:hpo ids='HP_0000001'>All</z:hpo>, but no tendency to <z:hpo ids='HP_0004416'>precocious atherosclerosis</z:hpo> is present </plain></SENT>
<SENT sid="1" pm="."><plain>To elucidate this paradox, the structure of <z:chebi fb="17" ids="39025">HDL</z:chebi>, the potential of serum to promote cholesterol efflux from cultured cells, and the in vivo metabolism of <z:chebi fb="17" ids="39025">HDL</z:chebi> were examined in a 53-year-old woman with a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FED</z:e> syndrome in association with a markedly decreased lecithin:cholesterol acyltransferase (LCAT) activity in <z:chebi fb="17" ids="39025">HDL</z:chebi> due to a mutation of the LCAT gene (Arg158 --&gt; Cys) </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="17" ids="39025">HDLs</z:chebi> isolated by ultracentrifugation were small and enriched in unesterified cholesterol and <z:chebi fb="1" ids="16247">phospholipids</z:chebi> at the expense of cholesteryl <z:chebi fb="21" ids="35701">esters</z:chebi> and proteins </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> content showed an enrichment in apo E and apo AIV, whereas apo AI and apo <z:hpo ids='HP_0000001'>All</z:hpo> were dramatically reduced </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="8984">Sodium dodecyl sulfate</z:chebi>-<z:chebi fb="0" ids="53656">polyacrylamide</z:chebi> gel electrophoresis (<z:chebi fb="26" ids="8984">SDS</z:chebi>-PAGE) and immunoblotting using specific antibodies showed that the apo E was free or covalently bound to apo <z:hpo ids='HP_0000001'>All</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>These particles analyzed by electron microscopy were small and round <z:chebi fb="2" ids="6495">lipoproteins</z:chebi> with a size similar to the smallest fraction of <z:mpath ids='MPATH_458'>normal</z:mpath> HDL3 </plain></SENT>
<SENT sid="6" pm="."><plain>The potential capacity of the serum to promote efflux from the cells was approximately 40% of control serum levels, but <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FED</z:e> <z:chebi fb="17" ids="39025">HDLs</z:chebi> were as efficient as control <z:chebi fb="17" ids="39025">HDLs</z:chebi> in promoting cholesterol efflux from cells </plain></SENT>
<SENT sid="7" pm="."><plain>To assess the metabolism of <z:chebi fb="17" ids="39025">HDL</z:chebi> <z:chebi fb="0" ids="39015">apolipoproteins</z:chebi>, in vivo <z:chebi fb="0" ids="39015">apolipoprotein</z:chebi> kinetic studies were performed using endogenous labeling techniques in the patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FED</z:e> and three control subjects </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> subjects were administered D3-labeled leucine by primed constant infusion for up to 10 hours </plain></SENT>
<SENT sid="9" pm="."><plain>The fractional synthetic rates (FSRs) of apo AI and apo <z:hpo ids='HP_0000001'>All</z:hpo> in the patient were 0.674 and 0.594 per day, clearly higher than in controls, 0.210 +/- 0.053 and 0.148 +/- 0.014 per day for apo AI and apo <z:hpo ids='HP_0000001'>All</z:hpo>, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>Apo AI and apo <z:hpo ids='HP_0000001'>All</z:hpo> production rates in the patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FED</z:e> were <z:mpath ids='MPATH_458'>normal</z:mpath>, 11.32 and 2.62 mg/kg x d, respectively, as compared with those in <z:mpath ids='MPATH_458'>normal</z:mpath> subjects, 11.45 +/- 1.23 and 2.68 +/- 0.17 mg/kg x d </plain></SENT>
<SENT sid="11" pm="."><plain>These data established that <z:e sem="disease" ids="C0473527" disease_type="Disease or Syndrome" abbrv="">hypoalphalipoproteinemia</z:e> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FED</z:e> was caused by marked hypercatabolism of apo AI and apo <z:hpo ids='HP_0000001'>All</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>This hypercatabolism could be the consequence of structural abnormalities due to the selective <z:e sem="disease" ids="C0268239" disease_type="Disease or Syndrome" abbrv="">LCAT deficiency</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>In conclusion, two steps of reverse cholesterol transport, cholesterol efflux and apo-<z:chebi fb="17" ids="39025">HDL</z:chebi> metabolism, appeared particularly efficient </plain></SENT>
<SENT sid="14" pm="."><plain>This efficiency could participate in the absence of <z:hpo ids='HP_0004416'>premature atherosclerosis</z:hpo> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FED</z:e> patients as regards the low <z:chebi fb="17" ids="39025">HDL</z:chebi> level </plain></SENT>
</text></document>